These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 35347023)

  • 1. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
    Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
    Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
    Yuan H; Li N; Wu L; Yao H
    J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
    Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 7. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
    J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
    Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
    J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
    Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.
    Guo Y; Chen X; Tang X; Pan S; Zhu T; Zhang Y
    Curr Cancer Drug Targets; 2024; 24(7):733-748. PubMed ID: 38173064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
    Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
    Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
    Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.